JGC
MACK

J. Goldman & Co’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

J. Goldman & Co’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-193,313
Closed -$587K – 373
2018
Q4 		$587K Buy
193,313
+66,213
+52% +$230K 0.05% 198
2018
Q3 		$533K Hold
127,100
– – 0.04% 221
2018
Q2 		$491K Buy
+127,100
New +$844K 0.03% 288
2017
Q3 		– Sell
-33,905
Closed -$331K – 453
2017
Q2 		$331K Buy
+33,905
New +$693K 0.02% 255

Other funds holding MACK

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

J. Goldman & Co's MACK Position: Q1 2019 in Review

J. Goldman & Co sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2019, closing a stake of 193,313 shares — an estimated $587K sold.

J. Goldman & Co first reported a position in MACK in Q2 2017 and held it in 4 quarters. The position peaked at $587K in Q4 2018. 54 funds tracked by Wall St. Rank hold MACK as of Q1 2019.

  • J. Goldman & Co reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • J. Goldman & Co sold 193,313 Merrimack Pharmaceuticals, Inc. shares in Q1 2019, an estimated $587K.
  • J. Goldman & Co first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2017 and held it in 4 quarters.
  • J. Goldman & Co's Merrimack Pharmaceuticals, Inc. position peaked at $587K in Q4 2018.
  • 54 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2019.

Based on J. Goldman & Co's 13F filing for Q1 2019, filed 14 May 2019.